• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

免疫组织化学检测浆细胞骨髓瘤中 CCND1、NSD2 和 MAF 基因重排。

Immunohistochemistry for identification of CCND1, NSD2, and MAF gene rearrangements in plasma cell myeloma.

机构信息

Department of Pathology and Molecular Diagnostics, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.

Department of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.

出版信息

Cancer Sci. 2019 Aug;110(8):2600-2606. doi: 10.1111/cas.14109. Epub 2019 Jul 11.

DOI:10.1111/cas.14109
PMID:31218784
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6676137/
Abstract

The t(11;14)/CCND1-IGH, t(4;14)/NSD2(MMSET)-IGH, and t(14;16)/IGH-MAF gene rearrangements detected by fluorescence in situ hybridization (FISH) are used for risk stratification in patients with multiple myeloma (MM). Compared with conventional FISH techniques using fresh cells, immunohistochemistry (IHC) is much more cost- and time-efficient, and can be readily applied to routinely prepared formalin-fixed, paraffin-embedded (FFPE) materials. In this study, we performed tissue FISH and IHC employing FFPE specimens, and examined the usefulness of IHC as a tool for detecting CCND1, NSD2, and MAF gene rearrangements. CD138 signals were used to identify plasma cells in tissue FISH and IHC analyses. With cohort 1 (n = 70), we performed tissue FISH and subsequently IHC, and determined IHC cut-off points. In this cohort, the sensitivity and specificity for the 3 molecules were ≥.90 and ≥.96, respectively. With cohort 2, using MM cases with an unknown gene status (n = 120), we performed IHC, and the gene status was estimated using the cut-off points determined with cohort 1. The subsequent FISH analysis showed that the sensitivity and specificity for the 3 molecules were ≥.92 and ≥.98, respectively. CCND1, NSD2, and MAF gene rearrangements were estimated accurately by IHC, suggesting that conventional FISH assays can be replaced by IHC.

摘要

荧光原位杂交 (FISH) 检测到的 t(11;14)/CCND1-IGH、t(4;14)/NSD2(MMSET)-IGH 和 t(14;16)/IGH-MAF 基因重排用于多发性骨髓瘤 (MM) 患者的风险分层。与使用新鲜细胞的传统 FISH 技术相比,免疫组织化学 (IHC) 更加经济高效,并且可以很容易地应用于常规制备的福尔马林固定、石蜡包埋 (FFPE) 材料。在这项研究中,我们使用 FFPE 标本进行组织 FISH 和 IHC 检测,并研究了 IHC 作为检测 CCND1、NSD2 和 MAF 基因重排的工具的有用性。在组织 FISH 和 IHC 分析中,CD138 信号用于识别浆细胞。使用队列 1(n=70),我们首先进行了组织 FISH,然后进行了 IHC,并确定了 IHC 的截断值。在该队列中,3 种分子的敏感性和特异性分别≥.90 和≥.96。在队列 2 中,我们使用基因状态未知的 MM 病例(n=120)进行 IHC,并使用队列 1 确定的截断值来估计基因状态。随后的 FISH 分析表明,3 种分子的敏感性和特异性分别≥.92 和≥.98。IHC 准确估计了 CCND1、NSD2 和 MAF 基因重排,表明可以用 IHC 替代传统的 FISH 检测。

相似文献

1
Immunohistochemistry for identification of CCND1, NSD2, and MAF gene rearrangements in plasma cell myeloma.免疫组织化学检测浆细胞骨髓瘤中 CCND1、NSD2 和 MAF 基因重排。
Cancer Sci. 2019 Aug;110(8):2600-2606. doi: 10.1111/cas.14109. Epub 2019 Jul 11.
2
Comprehensive FISH testing using FFPE tissue microarray of primary lymph node tissue identifies secondary cytogenetic abnormalities in Mantle Cell Lymphoma.应用 FFPE 组织微阵列对原发性淋巴结组织进行全面 FISH 检测可识别套细胞淋巴瘤中的继发细胞遗传学异常。
Cancer Genet. 2023 Jun;274-275:75-83. doi: 10.1016/j.cancergen.2023.04.002. Epub 2023 Apr 17.
3
Characterization of oncogene dysregulation in multiple myeloma by combined FISH and DNA microarray analyses.联合荧光原位杂交(FISH)和DNA微阵列分析对多发性骨髓瘤癌基因失调的特征分析
Genes Chromosomes Cancer. 2005 Feb;42(2):117-27. doi: 10.1002/gcc.20123.
4
CCND1 copy number increase and cyclin D1 expression in acral melanoma: a comparative study of fluorescence in situ hybridization and immunohistochemistry in a Chinese cohort.肢端黑色素瘤中 CCND1 拷贝数增加和 cyclin D1 表达:荧光原位杂交和免疫组织化学在中国队列中的比较研究。
Diagn Pathol. 2021 Jul 5;16(1):60. doi: 10.1186/s13000-021-01116-0.
5
Clinical Characteristics and Prognosis of MAF Deletion in Chinese Patients With Multiple Myeloma.中国多发性骨髓瘤患者中 MAF 缺失的临床特征和预后。
Clin Lymphoma Myeloma Leuk. 2019 Sep;19(9):e545-e550. doi: 10.1016/j.clml.2019.05.016. Epub 2019 May 29.
6
Molecular cytogenetic aberrations in patients with multiple myeloma studied by interphase fluorescence in situ hybridization.采用间期荧光原位杂交技术研究多发性骨髓瘤患者的分子细胞遗传学畸变。
Exp Oncol. 2007 Jun;29(2):116-20.
7
Differential nuclear organization of translocation-prone genes in nonmalignant B cells from patients with t(14;16) as compared with t(4;14) or t(11;14) myeloma.易位相关基因在 t(14;16)而非 t(4;14)或 t(11;14)骨髓瘤患者非恶性 B 细胞中的核组织差异。
Genes Chromosomes Cancer. 2013 Jun;52(6):523-37. doi: 10.1002/gcc.22049. Epub 2013 Mar 5.
8
Cytology specimens offer an effective alternative to formalin-fixed tissue as demonstrated by novel automated detection for ALK break-apart FISH testing and immunohistochemistry in lung adenocarcinoma.细胞学标本为福尔马林固定组织提供了一种有效的替代方法,新型自动化检测在肺腺癌的ALK断裂FISH检测和免疫组化中已证明了这一点。
Cancer Cytopathol. 2014 Nov;122(11):810-21. doi: 10.1002/cncy.21467. Epub 2014 Aug 5.
9
Chromatin-based, in cis and in trans regulatory rewiring underpins distinct oncogenic transcriptomes in multiple myeloma.基于染色质的顺式和反式调控重排为多发性骨髓瘤中的不同致癌转录组提供了基础。
Nat Commun. 2021 Sep 14;12(1):5450. doi: 10.1038/s41467-021-25704-2.
10
Involvement of the CCND1 gene in hairy cell leukemia.CCND1基因与毛细胞白血病的关系。
Ann Oncol. 1996 Mar;7(3):251-6. doi: 10.1093/oxfordjournals.annonc.a010568.

引用本文的文献

1
MAFB: a key regulator of myeloid commitment involved in hematological diseases.MAFB:参与血液系统疾病的髓系定向分化关键调节因子。
Cell Death Discov. 2025 Jun 12;11(1):276. doi: 10.1038/s41420-025-02551-4.
2
RNASeq Analysis for Accurate Identification of Fusion Partners in Tumor Specific Translocations Detected by Standard FISH Probes in Hematologic Malignancies.RNA测序分析用于在血液系统恶性肿瘤中通过标准荧光原位杂交探针检测到的肿瘤特异性易位中准确鉴定融合伙伴。
Clin Pathol. 2024 Feb 16;17:2632010X241230262. doi: 10.1177/2632010X241230262. eCollection 2024 Jan-Dec.
3
Molecular basis of clonal evolution in multiple myeloma.

本文引用的文献

1
Evaluation of the Revised International Staging System in an independent cohort of unselected patients with multiple myeloma.在未经选择的多发性骨髓瘤患者独立队列中对修订的国际分期系统进行评估。
Haematologica. 2017 Mar;102(3):593-599. doi: 10.3324/haematol.2016.145078. Epub 2016 Oct 27.
2
Cellular-level characterization of B cells infiltrating pulmonary MALT lymphoma tissues.浸润肺黏膜相关淋巴组织淋巴瘤组织的B细胞的细胞水平特征
Virchows Arch. 2016 Nov;469(5):575-580. doi: 10.1007/s00428-016-2012-z. Epub 2016 Sep 6.
3
Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia.
多发性骨髓瘤克隆进化的分子基础。
Int J Hematol. 2020 Apr;111(4):496-511. doi: 10.1007/s12185-020-02829-6. Epub 2020 Feb 6.
4
hsa_circ_0007841: A Novel Potential Biomarker and Drug Resistance for Multiple Myeloma.hsa_circ_0007841:一种用于多发性骨髓瘤的新型潜在生物标志物及耐药性相关指标
Front Oncol. 2019 Nov 19;9:1261. doi: 10.3389/fonc.2019.01261. eCollection 2019.
维奈托克单药治疗急性髓性白血病患者的II期研究中的疗效及反应的生物学关联
Cancer Discov. 2016 Oct;6(10):1106-1117. doi: 10.1158/2159-8290.CD-16-0313. Epub 2016 Aug 12.
4
Translocation t(11;14) in newly diagnosed patients with multiple myeloma: Is it always favorable?新诊断的多发性骨髓瘤患者中的11号与14号染色体易位:它总是有利的吗?
Genes Chromosomes Cancer. 2016 Sep;55(9):710-8. doi: 10.1002/gcc.22372. Epub 2016 Jun 24.
5
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group.多发性骨髓瘤修订国际分期系统:国际骨髓瘤工作组报告
J Clin Oncol. 2015 Sep 10;33(26):2863-9. doi: 10.1200/JCO.2015.61.2267. Epub 2015 Aug 3.
6
t(14;16)-positive multiple myeloma shows negativity for CD56 expression and unfavorable outcome even in the era of novel drugs.t(14;16)阳性多发性骨髓瘤即使在新型药物时代,CD56表达也呈阴性且预后不良。
Blood Cancer J. 2015 Feb 27;5(2):e285. doi: 10.1038/bcj.2015.6.
7
Immunohistological recognition of cyclin D1 expression by non-lymphoid cells among lymphoid neoplastic cells.免疫组织化学识别淋巴肿瘤细胞中的非淋巴细胞中环素 D1 的表达。
APMIS. 2014 Mar;122(3):183-91. doi: 10.1111/apm.12123. Epub 2013 Jun 12.
8
Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013.新诊断有症状多发性骨髓瘤的治疗:2013 年 Mayo 多发性骨髓瘤分层和风险适应性治疗(mSMART)共识指南更新版。
Mayo Clin Proc. 2013 Apr;88(4):360-76. doi: 10.1016/j.mayocp.2013.01.019.
9
Molecular pathogenesis of multiple myeloma: basic and clinical updates.多发性骨髓瘤的分子发病机制:基础与临床更新。
Int J Hematol. 2013 Mar;97(3):313-23. doi: 10.1007/s12185-013-1291-2. Epub 2013 Feb 28.
10
Fluorescence in situ hybridisation analysis of bone marrow trephine biopsy specimens; an additional tool in the diagnostic armoury.荧光原位杂交分析骨髓活检标本;诊断工具的又一补充。
J Clin Pathol. 2013 Jan;66(1):54-7. doi: 10.1136/jclinpath-2012-201131. Epub 2012 Oct 4.